AbbVie Announces High Sustained Virologic Response Rates In Phase 2 Studies With Pan-Genotypic, Investigational Regimen In Patients With Chronic Hepatitis C

Press/Media: Press / Media

PeriodNov 16 2015

Media coverage

1

Media coverage

  • TitleAbbVie Announces High Sustained Virologic Response Rates In Phase 2 Studies With Pan-Genotypic, Investigational Regimen In Patients With Chronic Hepatitis C
    Media name/outletBioSpace
    CountryUnited States
    Date11/16/15
    PersonsFred Poordad